To discover novel proteins that might participate in signalto generate physiological responses. The ing via heterotrimeric G proteins, a two-hybrid screen was established mechanism of PKA activation involves performed on a human testis library using G␣13 as bait. functional significance of the G␣13-AKAP110 and cotransformants were selected for ␤-galactosidase acinteraction, we have found that G␣13 induced tivity at 30ЊC for 4 days. ␤-galactosidase activity data indirelease of the cPKA from the AKAP110-rPKA cated that G␣13, but not G␣12, interacted with the complex, resulting in a cAMP-independent PKA AKAP110 fragments (Figure 1a ). The absence of interacactivation. Finally, AKAP110 significantly tion between AKAP110 and G␣12 was specific, because potentiated G␣13-induced activation of PKA. Thus, the same construct was used in the similar yeast two-AKAP110 provides a link between heterotrimeric G hybrid screen that yielded eight different positive clones proteins and cAMP-independent activation of PKA. coding for novel G␣12-interacting proteins (R. Vaisku-
G␣13 directly interacts with AKAP110 in an activationdependent manner in vitro
To confirm that the carboxyl-terminal domain of AKAP110 interacted directly with G␣13, we examined their binding using purified components in vitro. GST fusion proteins of both full-length AKAP110 and the puta- tive G␣13 binding domain interacted with purified G␣13 (Figure 1b) . Importantly, G␣13 bound to GST-AKAP110 Current Biology 2001 Biology , 11:1686 Biology -1690 (FL) and hydrolysis [4] . These data suggest that AKAP110 may function as a G␣ subunit effector protein. G␣13 interacts with AKAP110. (a) A specific interaction of AKAP110 beads were pulled down by centrifugation, and bound G␣13 was with G␣13 in yeast two-hybrid system. pB42AD constructs separated by SDS-PAGE and immunoblotted with antibody against containing full-length (AKAP-FL), 1-683 aa (AKAP-N) regions, and G␣13. C-350, C-terminal 350 amino acids; FL, full-length AKAP10. 685-853 aa (AKAP-C) regions of AKAP110 as indicated were (d) PKA, AKAP110, and G␣13 form a protein complex in vivo. transformed into yeast reporter strain EGY48 either with or without Coimmunoprecipitation of AKAP110 with G␣13. HEK-293 cells grown pLexA-G␣13Q226L or pLexA-G␣12Q229L. Cotransformants were in 10-cm 2 dishes were transiently transfected with vector alone or selected and underwent a ␤-galactosidase assay. The blue color with various Myc-tagged constructs of AKAP110 together with wildindicates a protein-protein interaction. (b) The domain structure of type HA-tagged G␣13. A total of 48 hr after transfection, cells were AKAP110. The domain that binds the regulatory subunit II of PKA, lysed, an equal amount of cell lysates was immunoprecipitated with the RII binding domain, is located between amino acids 124 and 141 agarose-conjugated anti-Myc antibodies in the presence or absence [3] . The putative G␣13 binding domain is located at 685-853 aa.
of AlF 4 Ϫ . Immunoprecipitates and cell lysates were analyzed by (c) Direct interaction of purified G␣13 protein with AKAP110 GST Western blotting using antibodies against Myc or HA. (e) fusion proteins in vitro. 1 M purified GST or GST-AKAP110 fusion Coimmunoprecipitation of AKAP110 with endogenous rPKA. The proteins bound to glutathione-sepharose beads were mixed with 0.25 same immunoprecipitates were probed with Myc antibodies or M purified G␣13-GDP in 100 l binding buffer to perform an in antibodies against RII. All experiments (b-e) were performed 3-4 vitro binding assay as described in the Materials and methods.
times with similar results. Where indicated, AlF 4 Ϫ was added. Glutathione-sepharose
G␣13 and AKAP110 form a protein complex in intact cells
and C-350 were ‫.4:1ف‬ Thus, it is likely that apparently weak interactions could be a result of lower expression To assess the in vivo interaction, we assayed the physical association between G␣13 and AKAP110 by coimmunoor stability of C-terminal domains of AKAP110. Both short (685-853 aa) and long (503-853 aa) C-terminal fragments, precipitation from human kidney embryonic 293 (HEK-293) cells transfected with Myc-tagged AKAP110 conbut not N-terminal (1-500 aa and 1-350 aa) fragments, bind to G␣13. The ability of the N-terminal domain to structs and HA-tagged G␣13. Western blotting showed that the expression of full-length AKAP110 is higher than interact with the RII subunit was performed as a positive control for the N-terminal domain activity (see the Supthe expression of any AKAP110 construct ( Figure 1e ). As it is not unusual for protein domains to be less stable than plementary material available with this article online). Thus, we have mapped the G␣13 binding site of AKAP110 full-length protein, we have determined relative intensities of the immunoprecipitated G␣13 and AKAP110 conto a region between residues 685 and 853 ( Figure 1e ). Consistent with results from the two-hybrid screen and structs' bands by densitometry using ImageQuant software. The ratios of G␣13 to AKAP110 full-length, C-170, in vitro binding, full-length AKAP110 bound only to an AlF 4 Ϫ -induced active state of G␣13. Additionally, AKAP110 interacted with the endogenous RII subunit. Interestingly, interaction of the G␣13 with AKAP110 did not affect the interaction of RII with AKAP110 ( Figure 1f ). These data suggest that AKAP110 can interact simultaneously with RII and G␣13 proteins and that G␣13 binding does not affect RII binding to AKAP110.
AKAP110 does not regulate GTPase activity or rate or nucleotide exchange activity
Some effector proteins, such as phospholipase C and cGMP phosphodiesterase ␥ subunit, also act as GTPaseactivating proteins (GAPs) that accelerate deactivation of heterotrimeric G proteins [5, 6 ]. Therefore, we tested whether AKAP110 affects the ability of G␣13 to hydrolyze GTP. AKAP110 did not stimulate GTPase activity of G␣13 over the untreated control (Figure 2a) . The positive control, p115RhoGEF, significantly stimulated GTPase activity at all time points. We also tested whether AKAP110 can regulate the rate of nucleotide exchange of G␣13 protein. In the absence of a receptor, the ratelimiting step for binding of the nonhydrolyzable GTP analog GTP␥S to the G␣ protein is the release of GDP. The full-length AKAP110 did not affect GTP␥S binding by G␣13 (Figure 2b ). Therefore, AKAP110 does not regulate GTPase activity or rate or nucleotide exchange activity.
Rho guanine nucleotide exchange factor, p115RhoGEF, is a recently identified G␣13 effector. G␣13 directly stimulates p115RhoGEF, leading to Rho activation [7, 8] 
activation.
G␣13 induces release of the PKA catalytic subunit from the AKAP110-RII complex fected the increasing concentrations of constitutively activated G␣13. Interestingly, both PKA activity and the To investigate the functional consequences of the interaction between AKAP110 and G␣13 in a heterologous examount of cPKA associated with AKAP110 was decreased, while the amount of RII detected by Western blotting did pression system, HEK-293 cells were transfected with cDNAs for AKAP110 (tagged with MYC) and were G␣13 not change in the presence of G␣13Q226L (Figure 3a) . Importantly, wild-type G␣13 did not affect PKA activity tagged with an HA epitope. Expression of AKAP110 and G␣13 did not change the amount of endogenous cPKA associated with AKAP110 ( Figure 3a) . Only G␣13Q226L, but not G␣iQ205L or G␣12Q229L, reduced PKA activity or rPKA, as determined by Western blotting of total cell lysates (data not shown). Both endogenous rPKA and associated with AKAP110, indicating that this effect by G␣13 is specific (Figure 3b ). cPKA coprecipitated with AKAP110 (Figure 3a) . PKA catalytic activity in immunoprecipitated material was determined in the absence or presence of 0.5 mM cAMP.
To confirm the observation that G␣13 induces the release of cPKA from the AKAP110 complex, AKAP110 was im-PKA activity was defined as the activity inhibited by 4 M PKA inhibitor PKI (Figure 3a) and was enriched by 58.4 Ϯ munoprecipitated from HEK-293 cells transiently transfected with Myc-tagged AKAP110. Preincubation of the 5-fold in the presence of cAMP (n ϭ 7). We then cotrans- ]adenine and were subjected to cAMP assay as with Myc-tagged AKAP110 together with either vector alone, described in the Materials and methods. (f) AKAP110 potentiates G␣iQ205L, G␣12Q229L, or G␣13Q226L as indicated. They were G␣13-induced VASP phosphorylation. Flag-tagged VASP was then lysed and immunoprecipitated with Myc antibodies, followed by cotransfected with G␣sR145C, G␣13Q226L, or AKAP110 as measurement of the PKA activity associated with AKAP110. (c) AlF 4 Ϫ -indicated. Cells were lysed, and the phosphorylation-dependent stimulated G␣13 induces the release of cPKA from the PKAelectrophoretic mobility shift of VASP was determined by AKAP110 complex in vitro. AKAP110 was immunoprecipitated from immunoblotting cell lysates with FLAG antibodies. All experiments transiently transfected HEK-293 cells as described above.
(b-f) were performed 3-4 times with similar results. Immunoprecipitates were incubated in 40 l kinase buffer in the immunocomplexes with 0.5 mM cAMP induced the re-PKA-specific activity stimulated with 0.2 M G␣13 was ‫6ف‬ pmol/min/U cPKA. These data suggest that purified lease of cPKA bound to rPKA into the supernatant ( Figure  3c ). This release was accompanied by a dramatic increase recombinant G␣13 can induce the release of catalytic subunits from the PKA-AKAP110 complex. This G␣13-in PKA activity (Figure 3a) . Preincubation of the immunocomplexes with AlF 4 Ϫ -activated G␣13 also induced the induced release of the catalytic subunit of PKA from the regulatory subunit of PKA did not require cAMP. release of cPKA, as determined by Western blotting and increased kinase activity (Figure 3c,d) . In a control experiment, G␣i2 did not affect PKA associated with AKAP110
Based on this data, we postulated that the G␣13-AKAP110 complex would enhance the cAMP-independent phosimmunocomplexes (Figure 3d) . We have quantitated relative PKA-specific activity as pmol of phosphate incorpophorylation of PKA substrates. The established mechanism of PKA activation in response to various hormones rated into the PKA substrate malantide per minute per unit of immunoprecipitated cPKA. An arbitrary unit of involves stimulatory G proteins, Gs, which activate adenylyl cyclase, resulting in the production of cAMP. Bindimmunoprecipitated cPKA was determined by Western blotting, followed by densitometry. PKA activity was deing of cAMP to rPKA leads to the release and activation of cPKA [2] . However, we have previously reported that termined as activity inhibited by 4 M PKI. The halfmaximal PKA-specific activity stimulated with 0.5 mM G␣13 does not induce the production of intracellular cAMP in HEK-293 cells [9] . This observation was concAMP was ‫06ف‬ pmol/min/U cPKA, and the half-maximal Another interesting possibility is that signal specificity is achieved (in addition to other mechanisms) via the interaction of ubiquitous signaling molecules with tissuespecific signaling molecules. Such signal specificity is probably the case in the G␣13-AKAP110 interaction, in which G␣13 is ubiquitously expressed, and AKAP110 expression is restricted to a few cell types. Thus, based on data showing that G␣13 regulates the actin cytoskeleton and that disruption of the AKAP110-PKA interaction blocks the sperm motility, we predict that the G␣13-AKAP110 interaction could be important in the regulation of sperm motility. An additional important physiological question about the role of the G␣13-AKAP110 interaction in the cerebellar neurons is based on data showing that G␣13 induces growth cone collapse in neuronal cell lines and AKAP110 is located in cerebellum neurons. Finally, a major challenge for future studies is to determine the molecular mechanism of G␣13-dependent release of cPKA from the AKAP110-RII complex.
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